Boston Scientific (NYSE:BSX) Price Target Raised to $132.00 at BTIG Research

Boston Scientific (NYSE:BSX) had its price target upped by BTIG Research from $127.00 to $132.00 in a research note released on Wednesday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Canaccord Genuity Group increased their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday. UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Finally, Leerink Partners began coverage on Boston Scientific in a research report on Monday, June 16th. They issued an “outperform” rating and a $118.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $120.67.

Boston Scientific Trading Down 1.9%

NYSE:BSX opened at $95.78 on Wednesday. The business has a fifty day moving average of $103.30 and a 200-day moving average of $102.08. Boston Scientific has a 1 year low of $80.64 and a 1 year high of $109.50. The stock has a market cap of $141.91 billion, a price-to-earnings ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the business posted $0.62 earnings per share. The company’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts predict that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Sound Income Strategies LLC increased its holdings in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the last quarter. 1248 Management LLC acquired a new position in shares of Boston Scientific during the 1st quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the 1st quarter valued at about $27,000. Finally, Kilter Group LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.